MCM
AZN icon

Matterhorn Capital Management’s AstraZeneca AZN Stock Holding History

Matterhorn Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-53,608
Closed -$3.5M – 56
2014
Q1 		$3.5M Sell
53,608
-462
-0.9% -$29.8K 1.62% 34
2013
Q4 		$3.21M Buy
54,070
+705
+1% +$38.3K 1.48% 41
2013
Q3 		$2.77M Buy
53,365
+1,405
+3% +$70.6K 1.39% 46
2013
Q2 		$2.46M Buy
+51,960
New +$2.65M 1.36% 44

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
MCM
Mason Capital Management New York $607M AUM 1.77% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SCCM
Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Matterhorn Capital Management's AZN Position: Q2 2014 in Review

Matterhorn Capital Management sold out of AstraZeneca (AZN) in Q2 2014, closing a stake of 53,608 shares — an estimated $3.5M sold.

Matterhorn Capital Management first reported a position in AZN in Q2 2013 and held it in 4 quarters. The position peaked at $3.5M in Q1 2014. 419 funds tracked by Wall St. Rank hold AZN as of Q2 2014.

  • Matterhorn Capital Management reported no remaining AstraZeneca position as of Q2 2014 after selling out during the quarter.
  • Matterhorn Capital Management sold 53,608 AstraZeneca shares in Q2 2014, an estimated $3.5M.
  • Matterhorn Capital Management first reported a position in AstraZeneca in Q2 2013 and held it in 4 quarters.
  • Matterhorn Capital Management's AstraZeneca position peaked at $3.5M in Q1 2014.
  • 419 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2014.

Based on Matterhorn Capital Management's 13F filing for Q2 2014, filed 8 Aug 2014.